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20 Oral Presentationsthan 12 months (Odds Ratio (OR) 3.7, CI 1.1, 11.8, P 5 .03) and
emotional distress pretransplant (OR 2.7, CI 1.0, 7.1, P5 .05). Re-
sults indicate that neuropsychological function continued to im-
proved from 1 to 5 years, but deficits remained for a third or
more of survivors in memory and motor dexterity.Impairment Rates at 5 Years
5 Year Survivors 5 Year Controls
Test % Impaired* % Impaired*Motor speed and dexterity
(Pegboard)43 17Verbal memory (HVLT) 32 20
Verbal fluency (COWAT) 20 14
Information processing
(Digit Symbol/Trails B)12/15 6/8*T scores in normative samples would have 15% impaired.48
A SIMPLIFIED SCORING SYSTEM TO PREDICT DAY 100 NON-RELAPSE
MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Basu, S.K.1, Liesveld, J.L.1, Trawick, D.R.2, Fernandez, D.3,
Nichols, D.1, Fisher, S.G.3. 1University of Rochester, Rochester, NY;
2University of Rochester, Rochester, NY; 3University of Rochester, Roches-
ter, NY.
This study’s purpose was to develop a scoring system using pa-
tient characteristics before hematopoietic stem cell transplantation
(HSCT) to predict the risk of early non-relapse mortality.
Methods: Patients undergoing their first HSCT at the Univer-
sity of Rochester from 1995 to 2004 were eligible. Non-relapse
mortality at 100 days (Day100NRM) was the primary outcome.
Sex, race, age, smoking status, body mass index, diagnosis, year,
transplant type, cell source, conditioning regimen, dose of nucle-
ated cells, diffusion capacity of the lung for carbon monoxide
(DLCO), forced expiratory volume at one second, forced vital ca-
pacity, creatinine, BUN, bilirubin, serum aspartate aminotransfer-
ase (AST), left ventricular ejection fraction, and albumin were
evaluated as independent variables. The study population was ran-
domly divided into two samples: an exploratory sample to construct
a prediction model with risk factors for Day100NRM and a valida-
tion sample to test this model. Results: Data regarding patient
characteristics were available on 677 (95%) patients. 507 subjects
(75%) were randomly selected to form the exploratory sample. Us-
ing logistic regression, related and unrelated allogeneic (versus au-
tologous) transplant, stem cells from bone marrow (versus
peripheral blood), low DLCO, low albumin, and high AST were
identified as statistically significant predictors of Day100NRM in
the exploratory sample (c-statistic 5 0.856). This model was suc-
cessfully validated (c-statistic 5 0.819) on the remaining 170 sub-
jects (validation sample) and on three random sub-samples of the
exploratory sample. Next, receiver operating characteristic curves
and classification tables were used to identify optimal cut-off points
to dichotomizeDLCO (\65,$65%predicted, corrected for hemo-
globin), AST (.40, #40 IU/L)) and albumin (\3.5, $3.5 g/dl) to
construct a scoring system for clinical use. This prediction model
was used to categorize patients into three groups- low, moderate,
or high risk of Day100NRM (see Table). There was an incremental
increase in risk of Day100NRM (2%, 13%, 39%) across the risk
groups. Conclusions: Type of transplant, stem cell source,
DLCO, AST, and albumin were predictive of Day100NRM, and
were used to construct a simplified scoring system. This pre-trans-
plant risk scoring system may be used for prognostication, and per-
haps to institute risk based targeted therapies. External validation is
necessary to determine its generalizability to other populations.Scoring System
Variable Variable ScoreDLCO (% predicted):\65 1
$65 0




Stem Cell source: Bone Marrow 1
Peripheral blood 0
Transplant: Unrelated donor 2
Related Donor 1
Autologous 0
Risk Group Total Score
Low Risk 0, 1
Moderate Risk 2
High Risk $349
RURAL-URBAN DISPARITIES IN SURVIVAL OUTCOME AFTER HEMATO-
POIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIG-
NANCIES
Rao, K.1, Darrington, D.L.2, Schumacher, J.J.2, DeVetten, M.P.2,
Vose, J.M.2, Loberiza, F.R.2. 1Brownell Talbott High School, Omaha,
NE; 2University of Nebraska Medical Center, Omaha, NE.
Background: We evaluated whether a patient’s area of primary
residence is an independent risk factor for overall survival (OS) after
HLA-identical sibling or autologous hematopoietic stem cell trans-
plantation (HSCT). Patients andMethods:This is a retrospective
study that included patients who received autologous HSCT (n 5
1739) for lymphoma and multiple myeloma (MM) or HLA-identi-
cal sibling (n5 267)HSCT for leukemias between 1983 and 2004 at
the University of Nebraska Medical Center. Primary area of resi-
dence using the patient’s zip code was categorized as either urban
or rural according to the Rural Urban Commuting Area Codes clas-
sifications. Association between area of primary residence and OS
was examined using Cox Proportional Hazards regression analysis
to adjust for other prognostic variables. The role of distance from
transplant center and average income were also explored. Results:
Patients coming from rural areas weremore likely to be: older, Cau-
casians, live at least 100 miles away, and have an average income
lower than $50K compared to patients coming from urban areas.
More rural patients are transplanted forMM, otherwise distribution
of diseases and disease stages were similar between the two areas.
The number of transplants performed in patients coming from rural
areas increased in the recent years. In the univariate analysis the fol-
lowing were associated with increased risk of death: patients from
rural areas, patients living more than 100 miles away, and patients
with income lower than $50K Inmultivariate analysis, among recip-
ients of autologous HSCT, patients from rural areas had an in-
creased risk of death (RR 1.18, P 5 0.016) compared to patients
from urban areas after adjusting for age, disease stage and time pe-
riod of transplant. The effect of distance and income dissipated.
Survival rates between rural and urban locations are: at 1 year
(73% vs. 78%, P 5 0.04) and at 5 years (48% vs. 54%, P 0.012).
We failed to detect a significant difference in the risk of death ac-
cording to area of residence in theHLA-identical siblingHSCT co-
hort, although this may be due to lack of statistical power.
Conclusion: The primary location of a patient’s residence may be
an independent risk factor for survival after HSCT. Specific issues
regarding the coordination of follow-up care of patients from rural
areas, as well as their health behavior and medical utilization pat-
terns post-HSCT should be studied prospectively.
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INCREASED RISK OF CERVICAL DYSPLASIA IN LONG TERM SURVIVORS
OF ALLOGENEIC STEM CELL TRANSPLANTATION – IMPLICATIONS FOR
SCREENING AND HPV VACCINATION
Savani, B.N.1,2, Shenoy, A.1, Stratton, P.3, Filie, A.4, Kozanas, E.1,
Chauvet, D.1, Donohue, T.1, Le, Q.1, Childs, R.W.1, Goodman, S.2,
Barrett, A.J.1. 1National Institutes of Health, Bethesda, MD; 2Veterans
AffairsMedical Center and Vanderbilt University Medical Center, Nash-
ville, TN; 3National Institutes of Health, Bethesda, MD; 4National In-
stitutes of Health, Bethesda, MD.
Cervical, skin and head-neck cancer are most common secondary
solid cancers in long-term survivors after allogeneic stem cell trans-
plantation (allo-SCT). Although these cancers are linked to human
papillomavirus (HPV) infection, the relationship betweenHPV and
cancers after allo-SCT is not defined. Furthermore, Pap smear
screening after SCT is not practiced routinely. We carried out
a cross-sectional study of 92 patients receiving allo-SCT for hema-
tological malignancies, enrolled at a minimumof 3 years post-trans-
plantation between 04/2005–06/2007 in an IRB-approved long-
term evaluation protocol.Ninety (98%) patients are alive after ame-
dian follow-up of 77 months (range 38–167). Evaluation of the 38
female patients (median age at transplant 33, range 9–60 years) in-
cluded annual gynecological examination. Thirty five received
a fractionated total body irradiation (TBI) (12–13.6 Gy) based mye-
loablative SCT and 3 received a non-TBI non-myeloablative SCT.
Acute graft versus host disease (GVHD) (grade II-IV) occurred in 9
(24%) patients and chronic GVHD in 34 (89%), extensive in 10
(26%). Six (16%) patients received immunosuppressive therapy
(IST) for chronic GVHD beyond 3 years from SCT. Thirty-five
(92%) adult patients had annual cervical smear examinations, 14
(40%) were abnormal. High grade dysplasia was seen in 8 (23%),
low grade lesions in 4 (11%) and 2 patients had atypical cells of un-
certain significance. Median time to an abnormal smear was 51
months (17–153) and median age of these 12 patients was 42 years
(range 19–62). Extensive chronic GVHD requiring prolonged
IST was the only factor associated with an increased risk of cervical
dysplasia (p 5 0.028). Our data shows that cervical dysplasia (often
high grade) is common after allo-SCT. These patients may be at in-
creased risk of developing invasive cervical cancer. Patients requir-
ing prolonged immunosuppression for chronic GVHD treatment
may be especially at risk for all forms of HPV-related malignancy.
Aggressive screening and preventive strategies with HPV vaccine
appear warranted.51
NATIONAL INSTITUTE OF HEALTH’S RECOMMENDATION FOR ASSESS-
ING LUNG FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION PREDICTS MORTALITY RISK
Walter, E.C.1,2, Orozco-Levi, M.3, Ramirez-Sarmiento, A.3,
Chien, J.W.1,2. 1University of Washington School of Medicine, Seattle,
WA; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Hospital
del Mar, Barcelona, Spain.
Background: The NIH recently published a consensus state-
ment that recommends monitoring FEV1 and DLCO to evaluate
changes in lung function after allogeneic hematopoietic cell trans-
plantation (aHCT). Although this recommendation was based
upon previous analysis of pre-transplant pulmonary function tests
(PFT), their clinical validity and utility have not yet been examined.
We conducted an analysis to determine whether FEV1 and DLCO
are the most informative measurements for post-transplant lung
function change by assessing their relationship with mortality after
aHCT.Methods:Weperformed a retrospective review of 1929 pa-
tients who underwent aHCT from 1993–2002 and received PFTs
within 60–100 days after transplant. Post-transplant FEV1, FVC,
TLC, and DLCO were categorized as ./580, 70–80, 60–70 and
\ 60% predicted. FEV1/FVC ratio was categorized as ./5 0.7
and\ 0.7. Per NIH recommendations lung function score (LFS,
range 2–12) was calculated using FEV1 and DLCO. LFS was
then categorized from 0–3 (category O 5 LFS 2; category 1 5
LFS 3–5; category 25LFS 6–9; category 35LFS 10–12).Results:
Two year all cause mortality after aHCTwas 32%. Univariate anal-ysis showed a stepwise increase in mortality with each categorical
decrease in FEV1, FVC, TLC, and DLCO. There was no signifi-
cant relationship between FEV1/FVC ratio and mortality. Mortal-
ity increased with increasing LFS (category 1 hazard ratio [HR],
1.50; category 2 HR, 2.86; category 3 HR, 5.64; p\0.001; c-statis-
tic 0.6). The LFS appeared to have a stronger association with mor-
tality than did any individual lung function parameter. However,
the LFS was not uniformly distributed with a significantly lower
number of patients in LFS categories 2 and 3 (mean LFS score
3.3). Summary: These results suggest that decreased lung function
by day 100 following aHCT is a risk factor for mortality. An ele-
vated LFS is associated with an increased risk of mortality. The
LFS may serve as a mechanism to grade severity of decreased
lung function in future clinical trials. However, the scoring system
may need to be altered to improve discrimination as it is currently
weighted towards patients with normal to near normal lung func-
tion. Abbreviations: FEV15Forced expiratory volume in 1 sec,
FVC5Forced vital capacity, TLC5Total lung capacity,
DLCO5Diffusion capacity of carbon monoxide.
Two year mortality as a function of post-transplant lung function
parameters and lung function score categories
Lung function
parameters Died (%) HR (95% CI) p-valueFEV1 (%) (n 5 1929)
.80 388/1397 (28) Referent
70–80 112/310 (36) 1.39 (1.13–1.72) 0.002
60–70 66/144 (46) 1.96 (1.51–2.55) \0.001
\60 56/78 (72) 3.84 (2.90–5.09) \0.001FVC (%) (n 5 1929)
.80 429/1545 (28) Referent
70–80 103/236 (44) 1.81 (1.46–2.25) \0.001
60–70 55/101 (54) 2.44 (1.85–3.24) \0.001
\60 35/47 (74) 4.19 (2.97–5.92) \0.001TLC (%) (n 5 1904)
.80 475/1644 (29) Referent
70–80 86/187 (46) 1.87 (1.49–2.36) \0.001
60–70 33/56 (59) 2.64 (1.85–3.76) \0.001
\60 13/17 (76) 4.35 (2.51–7.55) \0.001DLCO (%) (n 5 1893)
.80 245/995 (25) Referent
70–80 127/408 (31) 1.28 (1.03–1.59) 0.023
60–70 142/311 (46) 2.12 (1.72–2.60) \0.001
\60 91/179 (51) 2.50 (1.96–3.18) \0.001LFS category (n 5 1893)
0 (LFS 2) 205/849 (24) Referent
1 (LFS 3–5) 291/851 (34) 1.50 (1.25–1.79) \0.001
2 (LFS 6–9) 96/178 (54) 2.86 (2.25–3.65) \0.001
3 (LFS 10–12) 13/15 (87) 5.64 (3.22–9.88) \0.001Definition of abbreviations: CI5 confidence interval; LFS5 Lung
function score. Data was not available for all lung function
parameters for all patients.LEUKEMIA52
A SINGLE DOSE OF GEMTUZUMAB-OZOGAMICIN (GO) IN CONSOLIDA-
TION PRIOR TO AUTOLOGOUS TRANSPLANT FOR YOUNGER PATIENTS
WITH NEWLY DIAGNOSED ACUTE MYELOID (AML) IS SAFE BUT HAS
NO EFFECT ON DISEASE FREE SURVIVAL: INTERIM RESULTS OF EAST-
ERN COOPERATIVE ONCOLOGY GROUP STUDY (E1900)
Fernandez, H.F.1, Sun, Z.2, Bennett, J.M.3, Paietta, E.M.4,
Litzow, M.R.5, Rowe, J.M.6, Tallman, M.S.7, Lazarus, H.M.8. 1H.
Lee Moffitt Cancer Center, Tampa, FL; 2Eastern Cooperative Oncology
Group, Boston, MA; 3James P Wilmot Cancer Center, Rochester, NY;
4Our Lady of Mercy Cancer Center, Bronx, NY; 5Mayo Clinic College
of Medicine, Rochester, MN; 6Rambam Medical Center, Haifa, Israel;
7R. H. Lurie Cancer Center, Northwestern University, Chicago, IL;
